Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

19 Mar 2021

Abstract excerpt

Parkinson's Disease (PD) is characterized by primary and secondary plasticity that occurs in response to progressive degeneration and long-term L-DOPA treatment. Some of this plasticity contributes to the detrimental side effects associated with chronic L-DOPA treatment, namely L-DOPA-induced dyskinesia (LID). The dopamine D3 receptor (D3R) has emerged as a promising target in LID management as it is upregulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuroscience and Neuropharmacology Research
Share to Neurotransmitter Receptor Influence on Behavior
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33808538
DOI: 10.3390/biomedicines9030314

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced DyskinesiaPMID 33808538Read ↗

Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.Semantic proximity Read ↗

Signal transduction in l-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expressionSemantic proximity Read ↗

Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesiaSemantic proximity Read ↗

Differential activation states of direct pathway striatal output neurons associated with the development of L-DOPA-induced dyskinesiaSemantic proximity Read ↗

Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.Semantic proximity Read ↗

Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.Semantic proximity Read ↗

Selective expression of Parkinson's disease-relatedLeucine-rich repeat kinase 2G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expressionSemantic proximity Read ↗

Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson’s diseaseSemantic proximity Read ↗

Recent developments in the treatment of Parkinson's DiseaseSemantic proximity Read ↗

[The association of the DRD3 gene with Parkinson's disease].Semantic proximity Read ↗

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Repetitive Levodopa Treatment Drives Cell Type-Specific Striatal Adaptations Associated With Progressive Dyskinesia in Parkinsonian MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.